Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy

M. Svaton, J. Blazek, G. Krakorova, M. Pesek, M. Buresova, Z. Teufelova, J. Vodicka, K. Hurdalkova, M. Barinova, O. Topolcan

. 2021 ; 41 (4) : 2053-2058. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018891

AIM: To investigate potential associations between selected oncomarkers [carcinoembryonic antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell carcinoma antigen (SCC)] and outcomes in patients with NSCLC treated with bevacizumab plus chemotherapy. PATIENTS AND METHODS: We retrospectively analysed 105 patients with NSCLC from the Czech TULUNG registry treated at University Hospital in Pilsen with bevacizumab plus chemotherapy. Response to therapy was tested by Fisher's exact test. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: Only normal values of CYFRA (not CEA or SCC) were associated with significantly better overall and progression-free survival in univariate analysis. We also observed a trend for a better disease control rate in patients with normal levels of CYFRA. In a multivariate Cox model, only CYFRA was associated with significantly better overall but not progression-free survival. CONCLUSION: In our retrospective study, we point out the possibility of using CYFRA as a prognostic marker in patients with NSCLC treated with chemotherapy plus bevacizumab.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018891
003      
CZ-PrNML
005      
20251111160829.0
007      
ta
008      
210728s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.14974 $2 doi
035    __
$a (PubMed)33813413
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Svaton, Martin $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic; svatonm@fnplzen.cz
245    10
$a Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy / $c M. Svaton, J. Blazek, G. Krakorova, M. Pesek, M. Buresova, Z. Teufelova, J. Vodicka, K. Hurdalkova, M. Barinova, O. Topolcan
520    9_
$a AIM: To investigate potential associations between selected oncomarkers [carcinoembryonic antigen (CEA), C-terminus of cytokeratin 19 (CYFRA 21-1, CYFRA), and squamous cell carcinoma antigen (SCC)] and outcomes in patients with NSCLC treated with bevacizumab plus chemotherapy. PATIENTS AND METHODS: We retrospectively analysed 105 patients with NSCLC from the Czech TULUNG registry treated at University Hospital in Pilsen with bevacizumab plus chemotherapy. Response to therapy was tested by Fisher's exact test. Survival statistics were evaluated using the Kaplan-Meier method and Cox analysis. RESULTS: Only normal values of CYFRA (not CEA or SCC) were associated with significantly better overall and progression-free survival in univariate analysis. We also observed a trend for a better disease control rate in patients with normal levels of CYFRA. In a multivariate Cox model, only CYFRA was associated with significantly better overall but not progression-free survival. CONCLUSION: In our retrospective study, we point out the possibility of using CYFRA as a prognostic marker in patients with NSCLC treated with chemotherapy plus bevacizumab.
650    _2
$a senioři $7 D000368
650    _2
$a antigeny nádorové $x analýza $x krev $x fyziologie $7 D000951
650    _2
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a bevacizumab $x aplikace a dávkování $x škodlivé účinky $7 D000068258
650    _2
$a biomarkery farmakologické $x analýza $7 D054316
650    _2
$a nádorové biomarkery $x analýza $x fyziologie $7 D014408
650    _2
$a karcinoembryonální antigen $x analýza $x krev $7 D002272
650    _2
$a nemalobuněčný karcinom plic $x diagnóza $x farmakoterapie $x mortalita $x patologie $7 D002289
650    _2
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a keratin-19 $x analýza $x krev $x fyziologie $7 D053539
650    _2
$a nádory plic $x diagnóza $x farmakoterapie $x mortalita $x patologie $7 D008175
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a prediktivní hodnota testů $7 D011237
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a serpiny $x analýza $x krev $7 D015843
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
700    1_
$a Blazek, Jiri $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Krakorova, Gabriela $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Pesek, Milos $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Buresova, Marcela $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Teufelová, Zuzana $u Department of Pneumology and Phthisiology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic $7 xx0337764
700    1_
$a Vodicka, Josef $u Department of Surgery, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Hurdalkova, Karolina $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Barinova, Magda $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Topolcan, Ondrej $u Department of Nuclear Medicine, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 41, č. 4 (2021), s. 2053-2058
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33813413 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20251111160837 $b ABA008
999    __
$a ok $b bmc $g 1689855 $s 1139337
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 41 $c 4 $d 2053-2058 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace